Diacerein. A controversial EU re-evaluation upholds marketing authorisation, unfortunately.
Some national health authorities were in favour of market withdrawal of diacerein, a "slow-acting symptomatic" treatment for osteoarthritis, because of a disproportionate risk of adverse effects.